Why the Comparator Must Match the Regulatory Question
A bioequivalence result is a comparison between a test product and a particular reference product. The result therefore answers a specific question: how does this test product compare with this comparator, under the conditions of the study? It does not automatically establish equivalence to every product with the same active ingredient, nor does it guarantee that a regulator will accept the comparison for every application.
The regulatory reference product is the product a jurisdiction recognizes as the basis for the proposed comparison. The study comparator is the actual product administered to participants. A valid submission needs a defensible link between them: the administered product must be the reference product required or accepted for that application, and its identity and source must be documented. A brand name alone is not enough to establish that link.
The choice matters because the comparator defines the target of the inference. Suppose \(T\) denotes the test product and \(R\) the comparator, and let \(\mu_T\) and \(\mu_R\) be their mean log exposure values for a specified endpoint. The treatment contrast is \(\mu_T-\mu_R\). Changing \(R\) changes the contrast, even if the test product and study design stay the same. Passing a statistical criterion against one comparator does not establish that the same criterion would be met against another.
Designation Is Jurisdiction- and Application-Specific
Regulators use different terms and designation systems. These terms should be interpreted in the context of the intended submission, rather than treated as interchangeable names for any innovator-branded product.
- United States: The FDA identifies a reference listed drug (RLD) for an abbreviated new drug application. It also designates a reference standard for bioequivalence testing. The RLD and reference standard are often the same product, but they can differ. The applicable listing and current product-specific guidance should be checked to determine which product to use for the study and how it relates to the application.
- European Union: A generic application refers to a reference medicinal product (RMP) authorized in the relevant regulatory framework. The applicant must establish that the study comparator is an appropriate product for that reference and that its source satisfies the applicable requirements. The precise choice and sourcing expectations should be verified for the application and relevant authority.
- Other national and international pathways: A regulator may specify an acceptable comparator, use a published comparator list, or require a justification when the preferred product cannot be obtained. WHO guidance and national requirements may be relevant, but one authority’s accepted comparator does not automatically satisfy another authority’s requirements.
These distinctions are operational, not merely administrative. A product may be a legitimate comparator in one jurisdiction but not be the designated or accepted reference for a different jurisdiction or pathway. Before buying study supplies, identify the application type, the intended authority, the reference product required for that application, and any product-specific instructions. If the information is ambiguous, resolve the question with the authority or through an appropriate regulatory process before starting the study.
Worked Example: RLD and Reference Standard Are Not Assumed to Be Identical
A hypothetical U.S. application concerns an oral tablet. The current FDA records identify Product A as the RLD and Product B as the reference standard for the relevant strength. The study team has already obtained Product A and proposes to use it as the reference treatment.
Step 1: Identify the application’s reference. The team records Product A as the RLD. It does not infer that Product A must also be the reference standard: the records name Product B for that role.
Step 2: Check the study requirement. The team checks the current FDA listing and any applicable product-specific guidance. Because those records identify Product B as the reference standard, the team must not assume that using Product A is acceptable for the in vivo bioequivalence study.
Step 3: Resolve and document the choice before dosing. The team obtains Product B or seeks clarification on the applicable requirement before conducting the study. It records the product name, strength, dosage form, source, lot, and the regulatory basis for the choice.
Conclusion. Being the RLD does not, by itself, establish that a product is the correct study comparator when the designated reference standard differs. The current application-specific instructions determine the appropriate choice.
Verify Product Identity, Status, and Source
Once the relevant designation is known, confirm that the physical comparator matches it. At minimum, the review should establish the active ingredient or ingredients, dosage form, strength, route, and release characteristics. Check any product-specific requirements for salt or ester, formulation, packaging, or other identifying features. Products with the same active ingredient and strength can still differ in a way that makes them unsuitable for the intended comparison.
Authorization and market source also matter. Verify that the comparator is an authorized product from a source accepted by the intended regulator, rather than relying on a familiar brand name or an informal description such as “the original.” Keep records that allow the study supply to be traced to its source and lot. If a foreign-market product is proposed, do not assume that similarity in name, appearance, or labeling establishes its acceptability; determine whether the authority accepts that market version and what evidence is required.
A practical review can be organized as a sequence of checks:
Name the target jurisdiction, application pathway, product, strength, and dosage form. A comparator choice cannot be evaluated independently of this context.
Consult the current official listing, relevant guidance, and any application-specific instructions. Record the exact designation and the date or version checked.
Compare the comparator’s identity, formulation, strength, release properties, authorization, and market source with the regulatory requirement.
If the designated product is unavailable or the proposed supply differs, obtain the required justification or regulatory agreement before conducting the study.
Retain evidence of product identity, procurement, lot, expiry, storage, and the basis for treating the administered product as the required comparator.
Worked Example: A Foreign-Market Product Is Not Automatically the Same Comparator
A hypothetical applicant plans a submission to Authority Q. The authority’s current instructions identify Product C, authorized in Market Q, as the reference product. The preferred supply is temporarily unavailable. A distributor offers Product C from Market Z, with the same active ingredient, strength, and brand name.
Step 1: Separate product resemblance from regulatory acceptability. The matching name and strength are useful observations, but they do not prove that the Market Z supply is an acceptable comparator for the Market Q application.
Step 2: Check the relevant product attributes. The applicant verifies the dosage form, route, release characteristics, manufacturer and authorization information, and any other distinguishing features required by Authority Q. It also checks whether the authority permits sourcing the comparator from Market Z and whether additional evidence is needed.
Step 3: Decide based on the authority’s rule, not convenience. If the authority accepts the Market Z product subject to specified documentation, the applicant gathers that documentation before the study. If acceptance is uncertain or the product is not permitted, the applicant does not substitute it merely because it appears similar.
Conclusion. A foreign-market version may be acceptable in some circumstances, but the applicant must establish that under the rules for Authority Q. The brand name alone cannot establish regulatory equivalence of the comparator supply.
How Comparator Choice Changes the Interpretation
The dependence of the result on comparator identity can be shown directly. Suppose the geometric mean exposure is 102 units for a hypothetical test product. Against a designated comparator with geometric mean exposure of 100 units, the ratio is \(102/100=1.020\), or 102.0%. Against a different product with geometric mean exposure of 94 units, the ratio is \(102/94=1.085\), or 108.5%.
Both calculations are arithmetically correct, but they answer different comparison questions. Neither ratio alone establishes a regulatory conclusion: the relevant study design, uncertainty, applicable criteria, and required reference product all matter. In particular, a favorable estimate against an unaccepted comparator cannot replace the required comparison.
Worked Example: A Different Comparator Gives a Different Contrast
In a hypothetical study, the test product has a geometric mean exposure of 96 units. The designated comparator has a geometric mean exposure of 100 units. A second, non-designated product with the same active ingredient has a geometric mean exposure of 90 units. Calculate the ratios and explain which is relevant to the intended application.
Against the designated comparator:
Against the other product:
The second ratio is not interchangeable with the first: it uses a different denominator and therefore represents a different treatment contrast. For the intended application, the comparison against the designated comparator is the relevant one, unless the regulator has accepted a different comparator. These descriptive calculations do not by themselves determine whether the application meets the applicable bioequivalence criteria.
Alternatives, Diagnostics, and Limits
The main alternative to using the designated product is to use another product that the regulator has accepted as an appropriate comparator, or to seek approval for a proposed substitute when the designated product cannot be obtained. This may be necessary in practice, but it is not a unilateral choice by the study team. A published comparator list, a product-specific instruction, or written regulatory advice can provide the basis for an alternative. The applicant should preserve that basis in the study and submission records.
Several warning signs indicate that the selection process may have gone wrong:
- The protocol identifies only a brand name, without the regulatory designation or the exact product and source.
- The study product was selected because it was readily available, without checking current jurisdiction-specific instructions.
- The application’s RLD, reference standard, or RMP are treated as interchangeable despite evidence that their designations differ.
- A different strength, release type, dosage form, or market version is used without establishing that the regulator accepts it.
- Procurement records do not establish which manufacturer, market, lot, and authorization status correspond to the administered product.
- The comparator was changed after study planning without reassessing whether the study still addresses the intended regulatory question.
Comparator selection has limits: even a correctly chosen product does not guarantee a successful study or an acceptable application. The choice establishes the comparison target; it does not replace sound study conduct, suitable exposure measurements, or the applicable statistical and regulatory evaluation. Likewise, a study against one reference product does not automatically support claims against a different reference in another jurisdiction.
Common Mistake
Wrong reasoning: “The active ingredient and strength are the same, so any marketed version of the originator is an acceptable comparator.” This confuses pharmaceutical similarity with regulatory designation and ignores formulation, authorization, market source, and jurisdiction-specific requirements.
Correction: First identify the reference required or accepted for the exact application. Then verify that the study supply is that product, or that the authority has accepted the proposed alternative. Document the evidence before conducting the study. The intended regulator—not the study team’s assumption—determines whether the comparator is appropriate for the filing.
Check Your Understanding
Answer each question, then compare your reasoning with the solutions below.
- Why is the comparator in a bioequivalence study more than a convenient product containing the same active ingredient?
- In a U.S. application, what is the distinction between an RLD and a reference standard, and what should the sponsor do if the listings differ?
- A proposed comparator has the same brand name and strength as the reference but is sourced from another market. What must be established before it is used?
- A test product has a geometric mean exposure of 105 units. The designated comparator has 100 units, while another product has 95 units. Calculate both ratios and explain which comparison is relevant if the designated comparator is required.
- Name three records or product attributes that help establish comparator identity and traceability.
Solutions. (1) The comparator defines the target of the treatment contrast, and regulatory acceptance depends on the designated or accepted product for the application. (2) The RLD is the listed drug relied on for the abbreviated application, whereas the reference standard is designated for bioequivalence testing; consult current listings and guidance and follow the applicable study requirement rather than assuming the products are identical. (3) Establish that the other-market product is acceptable to the intended regulator and verify its identity, formulation, authorization, source, and any required supporting evidence. (4) The ratios are \(105/100=1.050\), or 105.0%, and \(105/95=1.105\), or 110.5%. If the designated comparator is required, the first ratio addresses the relevant comparison; the second does not substitute for it. (5) Examples include the product’s exact name and strength, dosage form and release characteristics, market and authorization details, manufacturer, source, lot number, expiry, and procurement records.